All News

HAQ.RAPID

RAPID3 in Assessing Psoriatic Arthritis

Jack Cush, MD

My research shows that up to 50% of rheumatologists measure something in the course of their daily assessments, and RAPID3 is most popular, being employed by 31% of rheumatologists.

Read Article
PSA2L.jpg

An Old Friend – Methotrexate in Psoriatic Arthritis

Pedro Castillo

Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been in the form of addition rather than substitution. But what do the patients want, and how much more is the MTX adding in those cases?

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Jack Cush, MD

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
unhappy%20patient.jpg

Psoriatic Arthritis: "What Matters" to Patients, Physicians

Swetha Ann Alexander, MD

A study presented today by Mease et al. addresses the vital gap between what patients and physicians consider disabling because of PsA, and emphasizes “what matters” in a daily clinical encounter while dealing with PsA.

Read Article
ACR Best

ACR21 Best Abstracts - Day 4

Jack Cush, MD

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

Read Article
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Jack Cush, MD

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
MDA in Psoriatic Arthritis: Dr. Rachel Tate ( @uptoTate) discusses abstract #1344 presented at the #ACR21 annual meeting. https://t.co/E5FNLYQ499 https://t.co/UvdQb3pM36

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: An Old Friend – Methotrexate in Psoriatic Arthritis Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, particularly in the care of peripheral arthritis such as PsA. https://t.co/kJdQ9Pd67v #ACR21 @_Castillo_Pedro https://t.co/lpvZJaPcYd

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Emerging Therapies in Psoriatic Arthritis: Drs. Antoni Chan ( @synovialjoints) interviews Dr. FitzGerald about abstract #0490 and other PsA highlights being presented at the #ACR21 annual meeting. https://t.co/1v8WhMkRHr https://t.co/UbqGkbupUM

Links:

Dr. John Cush RheumNow ( View Tweet)
Osteoporosis in PsA: Dr. Rachel Tate ( @uptoTate) discusses Abstract #1325, presented at the #ACR21 annual meeting. https://t.co/xnRkPnHeTr https://t.co/nE3ehhCB4j

Links:

Dr. John Cush RheumNow ( View Tweet)
RAPID3 in Psoriatic Arthritis: Dr. Meral El Ramahi ( @MeralElRamahiMD) reports on abstract #0633 presented at the #ACR21 annual meeting. https://t.co/DO7YXhD3YA https://t.co/vcegdPx8OL

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of PSA from Sunday Sessions: Dr. Rachel Tate ( @uptoTate) discusses the RheumNow PSA faculty's best PsA abstracts from Sunday sessions, including abstracts #0750 and #0944, which were presented at the #ACR21 annual meeting. https://t.co/wgMq2rsWNj https://t.co/Z2By90rBEy

Links:

Dr. John Cush RheumNow ( View Tweet)
Lipidomic Differences in PsA and RA: Dr. Pedro Castillo ( @_Castillo_Pedro) discusses abstract #0946 presented at the #ACR21 annual meeting. https://t.co/M8O1OdvFAk https://t.co/4QMgXPhLzn

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC ) #ACR21 https://t.co/jRLem8YWpv https://t.co/5EQB1Y38Xs

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis: What's with Brepocitinib? Dr. Eric Ruderman ( @JointMD ) discusses abstract #0488 presented at the #ACR21 annual meeting. https://t.co/mq0IMwyMSk https://t.co/oJAJS0DpQz

Links:

Dr. John Cush RheumNow ( View Tweet)
Targeting the HUGE dilemma!🎯 #Psoriatic vs Erosive #OA PsA 👉 Fluffy bone formation(enthesitis of phalanges) 👉 Marginal erosions(vs central) 👉 Many jts in same digit(ray inv) 👉 Periarticular SOFT tissue swelling (dactylitis). 👉 NOT much hand OA #ACR21 RadiologyBootCamp https://t.co/OQLPoeRLny
Ashima Makol MD AshimaMakol ( View Tweet)
Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2 Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteria https://t.co/YPc5fx9wAR #ACR21 Abst1945 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions. 🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use. 🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs https://t.co/Id658ocDVf #ACR21 Abst1777 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

⭐️From 2012 – 2017 NIS data significant 🔽 in sepsis, SSTI, and UTI in patients with PsA despite the increased use of biologics over the years ⭐️No statistical difference pneumonia trend in PsA Abst# 1783 #ACR21 @Rheumnow https://t.co/ToxgRb0acP
swethaann23 swethaann23 ( View Tweet)
Direct-to-Patient (DA) PsA Screening Survey sent to patients with Ps without PsA led to earlier diagnosis of PsA in 0.4%(n=1149 patients) as compared to 0.3%(n=1150) receiving standard of care (SOC). Mean times to PsA diagnosis 66d ▶️ DA 77d ▶️SOC Abst# 1781 #ACR21 @RheumNow https://t.co/qxjPCU0vnI
swethaann23 swethaann23 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×